Financials
Financial year 2025
Anima Research from Alken, company number BE0452135608, closed financial year 2025 with a result of € -2.2 million after tax. For that financial year Anima Research recorded a gross margin of € -1.3 million and equity of € 2.7 million. Compared with financial year 2024, the result moved from € 531,056 to € -2.2 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 23, 2026.
€ 2.7 million
▼ 45% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.2 million
▼ still € 531,056 profit in 2024
Profit after tax over the fiscal year.
€ 600,785
▼ 83% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 953,269.
People and assets in 2025
6
▼ 1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 544,814
▲ 20% vs 2024
€ 90,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 129,676
▲ 12% vs 2024
Of which on lease € 23,166.
Debts at end 2025
€ 435,223
▼ 76% vs 2024
€ 24,753 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 1.1 million
▲ 135% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 42,904
▼ 44% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 1,062,046 | € 2,678,227 | € 1,959,566 | € -1,251,176 | ▼ € 3.2 million |
| Profit after taxes | € 231,387 | € 1,304,213 | € 531,056 | € -2,218,260 | ▼ € 2.7 million |
| Equity | € 1,399,760 | € 2,703,973 | € 4,835,029 | € 2,666,769 | ▼ 45% |
| Total debts | € 3,179,813 | € 2,008,732 | € 2,411,758 | € 1,557,942 | ▼ 35% |
| Cash | € 228,385 | € 92,650 | € 3,566,412 | € 600,785 | ▼ 83% |
| Land & buildings | € 473,082 | € 451,057 | € 499,087 | € 485,569 | ▼ 3% |
| Retained profit | € 1,336,260 | € 2,640,473 | € 3,171,529 | € 953,269 | ▼ 70% |
| Dividend | € 54,267 | € 0 | € 0 | € 0 | |
| Bank debt | € 1,397,624 | € 297,557 | € 1,834,348 | € 435,223 | ▼ 76% |
| Balance sheet total | € 4,579,573 | € 4,712,706 | € 7,246,787 | € 4,322,012 | ▼ 40% |
| Employees (FTE) | 3.9 | 5 | 7 | 6 | ▼ 1 |
Key figures of Anima Research, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Anima Research?
What happened at Anima Research in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 2.2 million (▼ € 2.7 million vs 2024). filed late Source: NBB ↗
- SB CLINICAL CONSULTING BV became a director. NBB
- LINDE BUNTINX BV became a director. NBB
- EB PHARMA DEVELOPMENTS BV became a director. NBB
- BNP PARIBAS FORTIS PRIVATE EQUITY MANAGEMENT became a director. NBB
- BAMBRIDGE BV became a director. NBB
- New establishment in Diepenbeek. KBO
- New establishment in Alken. KBO
In short
From € 231,387 profit in 2022 to € 2.2 million loss in 2025.
Paid € 940,970 in corporate taxes since 2022.
Best year ever: 2023, with € 1.3 million profit.
On average € 279,900 of value added per employee in 2024.
Management
The stake of BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Anima ResearchBehind Anima Research are EB PHARMA DEVELOPMENTS BV, LINDE BUNTINX BV, BNP PARIBAS FORTIS PRIVATE EQUITY MANAGEMENT, BAMBRIDGE BV and SB CLINICAL CONSULTING BV. The shares are held by EQUITY BNP PARIBAS FORTIS PRIVATE (20%), STIJN BOLLEN (0.7%), RESEARCH ANIMA (0.7%), ERIK BUNTINX and BNP PARIBAS FORTIS PRIVATE EQUITY BELGIUM (20%). It owns 100% of ANIMA CLINICAL itself.
Directors
According to the 2025 annual accounts
since 2024
Director · represented by BUNTINX ERIK
Also active at: INTEGRA INVEST Alken, INTEGRA
since 2024
BNP PARIBAS FORTIS PRIVATE EQUITY MANAGEMENT
Director · represented by VERMEULEN SVEN
Also active at: HET ANKER, STUDIO 100, PLOPSA, THEODORUS III, QBIC Feeder Fund, QBIC Arkiv Fund, QBIC Brussels Fund
since 2024
Director · represented by DE CLIPPEL ERIK
Also active at: DEGROOF PETERCAM CORPORATE FINANCE
since 2024
Director · represented by BOLLEN STIJN
since 2026
Shareholders
EQUITY BNP PARIBAS FORTIS PRIVATE
20%
STIJN BOLLEN
0.7%
RESEARCH ANIMA
0.7%
ERIK BUNTINX
Participations
100%
Establishments
Establishment units
Physical locations of this company
Alkerstraat 28
3570 Alken
Wetenschapspark 11-13
3590 Diepenbeek
Active since 1 April 2021
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0452.135.608
- VAT number
- BE 0452.135.608
- Registered office
- Alkerstraat 28, 3570 Alken
- Names & denominations
- Anima Research
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 5 February 1994
- Peppol
- Active · Active since 1 Dec 2025
- Contact
- 011/31.62.72
- Activities · NACE
Activiteiten van medisch specialisten
Medische praktijken
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige technische testen en toetsen